Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 13, 2021

SELL
$5.03 - $8.8 $1.55 Million - $2.72 Million
-308,800 Reduced 96.77%
10,300 $64,000
Q3 2020

Nov 12, 2020

SELL
$3.64 - $7.76 $110,656 - $235,904
-30,400 Reduced 8.7%
319,100 $1.34 Million
Q2 2020

Aug 12, 2020

SELL
$4.78 - $8.26 $3.4 Million - $5.87 Million
-710,800 Reduced 67.04%
349,500 $2.42 Million
Q1 2020

May 13, 2020

BUY
$4.0 - $21.53 $2.93 Million - $15.7 Million
731,300 Added 222.28%
1,060,300 $4.24 Million
Q4 2019

Feb 10, 2020

SELL
$13.94 - $24.12 $4.23 Million - $7.32 Million
-303,400 Reduced 47.98%
329,000 $7.05 Million
Q3 2019

Nov 14, 2019

SELL
$13.89 - $23.16 $233,352 - $389,088
-16,800 Reduced 2.59%
632,400 $9.59 Million
Q2 2019

Aug 14, 2019

BUY
$16.27 - $20.51 $3.94 Million - $4.97 Million
242,400 Added 59.59%
649,200 $12.6 Million
Q1 2019

May 15, 2019

SELL
$12.61 - $22.33 $7.06 Million - $12.5 Million
-559,900 Reduced 57.92%
406,800 $8.45 Million
Q4 2018

Feb 14, 2019

SELL
$12.41 - $22.98 $15.3 Million - $28.4 Million
-1,236,500 Reduced 56.12%
966,700 $13.2 Million
Q3 2018

Nov 14, 2018

BUY
$2.45 - $16.27 $5.35 Million - $35.5 Million
2,182,200 Added 10391.43%
2,203,200 $35.8 Million
Q2 2018

Aug 14, 2018

SELL
$2.68 - $3.48 $236,376 - $306,936
-88,200 Reduced 80.77%
21,000 $65,000
Q1 2018

May 15, 2018

SELL
$2.99 - $4.44 $73,853 - $109,668
-24,700 Reduced 18.45%
109,200 $329,000
Q4 2017

Feb 14, 2018

BUY
$3.06 - $4.09 $277,236 - $370,554
90,600 Added 209.24%
133,900 $537,000
Q3 2017

Nov 14, 2017

BUY
$3.03 - $3.72 $131,199 - $161,076
43,300
43,300 $152,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $185M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.